Bristol Myers tightens admilparant monitoring after liver damage, death
AI Summary- Bristol Myers Squibb amended Aloft trial monitoring for admilparant’s liver-related safety risks.
- One participant died after multi-organ failure involving liver damage, immune damage and widespread clotting.
- Bristol Myers Squibb expects to report study results by the end of the year.